%PDF-1.3
%ºß¬à
3 0 obj
<</Type /Page
/Parent 1 0 R
/Resources 2 0 R
/MediaBox [0 0 595.2799999999999727 841.8899999999999864]
/Contents 4 0 R
>>
endobj
4 0 obj
<<
/Length 6378
>>
stream
0.5670000000000001 w
0 G
BT
/F1 10 Tf
11.5 TL
0.439 g
411.0280314960629084 827.7167716535433328 Td
(AI-generated content may be incorrect) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 813.5435433070865656 Td
(Draft Document) Tj
ET
1.4173228346456694 w
28.3464566929133888 807.8742519685039269 m
198.4251968503937178 807.8742519685039269 l
S
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 785.1970866141732586 Td
(Company: Contoso) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 756.8506299212598378 Td
(Name: Ritesh Mate \(Persistent\)) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 728.5041732283464171 Td
(FOA ID: ) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 700.15771653543311 Td
(FOA Title: ) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 671.8112598425196893 Td
(Research Topic: The effects of influenza vaccine on immunocompromised persons) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 643.4648031496062686 Td
(Title: Project Summary) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 615.1183464566928478 Td
(## Project Summary) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 586.7718897637794271 Td
(The research project aims to investigate the effects of influenza vaccine on) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 572.5986614173227736 Td
(immunocompromised individuals. Immunocompromised persons, including those with solid) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 558.42543307086612 Td
(organ transplants, hematopoietic stem cell transplants, solid cancers, hematologic malignancy,) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 544.2522047244094665 Td
(and autoimmune conditions receiving biologic therapies, are at high risk of complications from) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 530.0789763779526993 Td
(influenza infection. Despite the challenges of low vaccine immunogenicity in this population,) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 515.9057480314959321 Td
(some evidence suggests that the influenza vaccine can be effective in reducing severe disease.) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 501.7325196850393354 Td
(Various strategies have been explored to enhance vaccine immunogenicity, such as high-dose) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 487.559291338582625 Td
(vaccines, adjuvanted vaccines, and intradermal vaccines. The project will focus on evaluating) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 473.3860629921259147 Td
(the impact of different influenza vaccine strategies in immunocompromised individuals to) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 459.2128346456692611 Td
(improve vaccine effectiveness and protect this vulnerable population from influenza-related) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 445.0396062992125508 Td
(morbidity and mortality.) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 402.5199212598424765 Td
(Title: Project Narrative) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 374.1734645669290558 Td
(### Project Narrative) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 360.0002362204724022 Td
(The research project aims to investigate the impact of influenza vaccine on) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 345.8270078740156919 Td
(immunocompromised individuals, including those with solid organ transplants, hematopoietic) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 331.6537795275589815 Td
(stem cell transplants, solid cancers, hematologic malignancy, and autoimmune conditions) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 317.480551181102328 Td
(receiving biologic therapies. The study will focus on evaluating the effectiveness and) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 303.3073228346455608 Td
(immunogenicity of the seasonal influenza vaccine in this vulnerable population. By analyzing the) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 289.1340944881889072 Td
(existing evidence on vaccine efficacy, immunogenicity, and strategies to enhance vaccine) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 274.9608661417322537 Td
(response, the research seeks to provide valuable insights into optimizing influenza vaccination) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 260.7876377952754865 Td
(protocols for immunocompromised persons.) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 218.2679527559054122 Td
(Title: Facilities & Resources) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 189.9214960629919915 Td
(### Facilities & Resources) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 161.5750393700786844 Td
(The research project on "The effects of influenza vaccine on immunocompromised persons" will) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 147.4018110236219172 Td
(require access to the following facilities and resources:) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 119.0553543307086102 Td
(1. **Laboratory Facilities**: Equipped with necessary tools for sample analysis and vaccine) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 104.882125984251843 Td
(effectiveness testing.) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 90.7088976377951894 Td
(   ) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 76.5356692913385359 Td
(2. **Clinical Research Center**: To conduct trials and studies involving immunocompromised) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 62.3624409448817687 Td
(individuals receiving the influenza vaccine.) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 34.0159842519684616 Td
(3. **Data Management System**: To securely store and analyze data collected during the) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 19.8427559055116944 Td
(research study.) Tj
ET
endstream
endobj
5 0 obj
<</Type /Page
/Parent 1 0 R
/Resources 2 0 R
/MediaBox [0 0 595.2799999999999727 841.8899999999999864]
/Contents 6 0 R
>>
endobj
6 0 obj
<<
/Length 5872
>>
stream
1.4173228346456694 w
0 G
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 785.1970866141732586 Td
(4. **Specialized Equipment**: Such as high-dose influenza vaccines, adjuvanted vaccines, and) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 771.0238582677164914 Td
(intradermal vaccines for comparative studies.) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 742.6774015748030706 Td
(5. **Qualified Personnel**: Including researchers, clinicians, and support staff experienced in) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 728.5041732283464171 Td
(working with immunocompromised populations and vaccine trials.) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 700.15771653543311 Td
(6. **Ethics Review Board Approval**: Ensuring all research protocols adhere to ethical standards) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 685.9844881889763428 Td
(and guidelines.) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 657.6380314960629221 Td
(7. **Funding**: To support the procurement of necessary supplies, participant compensation,) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 643.4648031496062686 Td
(and overall research operations.) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 615.1183464566928478 Td
(These facilities and resources are essential for conducting a comprehensive study on the effects) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 600.9451181102361943 Td
(of influenza vaccine on immunocompromised persons.) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 558.42543307086612 Td
(Title: Research Plan) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 530.0789763779526993 Td
(### Research Plan) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 501.7325196850393354 Td
(**Specific Aims:**) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 487.559291338582625 Td
(- Identify the specific objectives and goals of the research focusing on the effects of influenza) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 473.3860629921259147 Td
(vaccine on immunocompromised persons.) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 459.2128346456692611 Td
(- Clearly outline how these goals will be achieved through the study.) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 430.8663779527558404 Td
(**Research Strategy:**) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 416.69314960629913 Td
(- Establish an administrative infrastructure to oversee the implementation of activities related to) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 402.5199212598424765 Td
(the research project.) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 388.3466929133857661 Td
(- Describe how the research team will provide support for addressing the research hypotheses) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 374.1734645669290558 Td
(concerning immunocompromised individuals.) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 360.0002362204724022 Td
(- Detail the management plan for resources, subcontractors, and consultants.) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 345.8270078740156919 Td
(- Explain the communication strategy among collaborators and stakeholders.) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 317.480551181102328 Td
(**Immunological Analyses:**) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 303.3073228346455608 Td
(- Describe the immunological analyses that will be conducted to assess the impact of influenza) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 289.1340944881889072 Td
(vaccination on immunocompromised individuals.) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 274.9608661417322537 Td
(- Explain the rationale for including control groups in the study.) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 260.7876377952754865 Td
(- Outline strategies for identifying and characterizing human subjects, including data collection) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 246.614409448818833 Td
(and sample quality standards.) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 218.2679527559054122 Td
(**Data Management Plan:**) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 204.0947244094487587 Td
(- Detail internal and external data acquisition strategies to ensure harmonization of data) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 189.9214960629919915 Td
(management procedures.) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 175.748267716535338 Td
(- Describe how data quality, analyses, and dissemination will be managed.) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 161.5750393700786844 Td
(- Explain how data uniformity and high-quality content will be maintained across all study sites.) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 147.4018110236219172 Td
(- Provide details on training for data and sample collection procedures.) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 119.0553543307086102 Td
(This research plan aims to investigate the effects of influenza vaccine on immunocompromised) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 104.882125984251843 Td
(individuals, emphasizing the importance of immunological analyses and robust data) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 90.7088976377951894 Td
(management practices.) Tj
ET
endstream
endobj
7 0 obj
<</Type /Page
/Parent 1 0 R
/Resources 2 0 R
/MediaBox [0 0 595.2799999999999727 841.8899999999999864]
/Contents 8 0 R
>>
endobj
8 0 obj
<<
/Length 245
>>
stream
1.4173228346456694 w
0 G
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 813.5435433070865656 Td
(Signature: ) Tj
ET
BT
/F1 12 Tf
13.7999999999999989 TL
0. g
28.3464566929133888 785.1970866141732586 Td
(Additional Signature: ) Tj
ET
endstream
endobj
1 0 obj
<</Type /Pages
/Kids [3 0 R 5 0 R 7 0 R ]
/Count 3
>>
endobj
9 0 obj
<<
/Type /Font
/BaseFont /Helvetica
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
10 0 obj
<<
/Type /Font
/BaseFont /Helvetica-Bold
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
11 0 obj
<<
/Type /Font
/BaseFont /Helvetica-Oblique
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
12 0 obj
<<
/Type /Font
/BaseFont /Helvetica-BoldOblique
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
13 0 obj
<<
/Type /Font
/BaseFont /Courier
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
14 0 obj
<<
/Type /Font
/BaseFont /Courier-Bold
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
15 0 obj
<<
/Type /Font
/BaseFont /Courier-Oblique
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
16 0 obj
<<
/Type /Font
/BaseFont /Courier-BoldOblique
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
17 0 obj
<<
/Type /Font
/BaseFont /Times-Roman
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
18 0 obj
<<
/Type /Font
/BaseFont /Times-Bold
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
19 0 obj
<<
/Type /Font
/BaseFont /Times-Italic
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
20 0 obj
<<
/Type /Font
/BaseFont /Times-BoldItalic
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
21 0 obj
<<
/Type /Font
/BaseFont /ZapfDingbats
/Subtype /Type1
/FirstChar 32
/LastChar 255
>>
endobj
22 0 obj
<<
/Type /Font
/BaseFont /Symbol
/Subtype /Type1
/FirstChar 32
/LastChar 255
>>
endobj
2 0 obj
<<
/ProcSet [/PDF /Text /ImageB /ImageC /ImageI]
/Font <<
/F1 9 0 R
/F2 10 0 R
/F3 11 0 R
/F4 12 0 R
/F5 13 0 R
/F6 14 0 R
/F7 15 0 R
/F8 16 0 R
/F9 17 0 R
/F10 18 0 R
/F11 19 0 R
/F12 20 0 R
/F13 21 0 R
/F14 22 0 R
>>
/XObject <<
>>
>>
endobj
23 0 obj
<<
/Producer (jsPDF 2.5.2)
/CreationDate (D:20250619155614+05'30')
>>
endobj
24 0 obj
<<
/Type /Catalog
/Pages 1 0 R
/OpenAction [3 0 R /FitH null]
/PageLayout /OneColumn
>>
endobj
xref
0 25
0000000000 65535 f 
0000013076 00000 n 
0000014909 00000 n 
0000000015 00000 n 
0000000152 00000 n 
0000006582 00000 n 
0000006719 00000 n 
0000012643 00000 n 
0000012780 00000 n 
0000013145 00000 n 
0000013270 00000 n 
0000013401 00000 n 
0000013535 00000 n 
0000013673 00000 n 
0000013797 00000 n 
0000013926 00000 n 
0000014058 00000 n 
0000014194 00000 n 
0000014322 00000 n 
0000014449 00000 n 
0000014578 00000 n 
0000014711 00000 n 
0000014813 00000 n 
0000015161 00000 n 
0000015247 00000 n 
trailer
<<
/Size 25
/Root 24 0 R
/Info 23 0 R
/ID [ <B7A7116384B2C9675B558C69CF682C9F> <B7A7116384B2C9675B558C69CF682C9F> ]
>>
startxref
15351
%%EOF